Global Lentiviral Vectors Market Report and Forecast 2024-2032

Global Lentiviral Vectors Market Outlook

The global lentiviral vectors market size was valued at USD 202.81 million in 2023, driven by the increasing prevalence of diabetes and increasing research and development activities across the globe. The market size is anticipated to grow at a CAGR of 15.1% during the forecast period of 2024-2032 to achieve a value of USD 719.05 million by 2032.

Lentiviral Vectors: Introduction

Lentiviral vectors are specialized instruments used in gene therapy and genetic engineering. They originated from a retrovirus family member called lentivirus, a particular class of virus. Given that lentiviruses may infect both proliferating and non-dividing cells, they are beneficial for transferring genetic material into a variety of cell types, including challenging-to-transfect cells like stem cells and neurons.

Lentiviral vectors are lentiviruses that have been modified for the goal of controlled and safe gene delivery. For a variety of purposes, including gene therapy, genetic research, and experimental studies, they can be used to introduce genes or genetic material into target cells.

Global Lentiviral Vectors Market Analysis

The global market for lentiviral vectors is witnessing significant growth in the market and is anticipated to keep growing in the coming years as well. Factors such as the increasing research and development activities by key players and a significant shift towards patient centric healthcare are directly driving the lentiviral vectors market growth. Key players across the globe are now taking initiative towards collaborating with each other to produce more effective treatments of genetic disorders caused by single-gene mutations, such as severe combined immunodeficiency (SCID), hemophilia, muscular dystrophy, and certain types of blindness. The success of recent clinical trials using lentiviral vectors for certain genetic disorders, as it provides reliable techniques to deliver therapeutic genes into cells, has further fueled the demand for lentiviral vectors in the global market.

In response to the growing demand for starting materials for use in cell therapy, a leading cell therapy company based in the United States is creating allogeneic genetically modified CAR-NK cells using umbilical cord blood and has announced a collaboration agreement with California-based regenerative therapeutics company StemCyte. This collaboration is expected to further propel market growth as it is expected to cater as a catalyst for advancements and growth in the market.

Global Lentiviral Vectors Market Segmentations

Market Breakup by Components

• Lentiviral Promoter

• Lentiviral Fusion Tags

• Lentivirus Packaging Systems

Market Breakup by Indications

• Cancer

• Genetic Disorders

• Infectious Diseases

• Veterinary Disease

• Other

Market Breakup by Applications

• Gene Therapy

• Vaccinology

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Lentiviral Vectors Market Overview

The increasing geriatric population worldwide is a major factor driving the market growth. The increasing prevalence of chronic diseases, such as diabetes, are also contributing to the market growth due to the need for gene therapy improving glycemic control and reducing the need for insulin therapy.

According to WHO, diabetes was the cause of death of over 1.5 million people aged below 70 years of age in 2020. Lentiviral vectors are used to cure a wide range of disorders that are genetically influenced, such as cancer immunotherapy, neurodegenerative disease, hematopoietic disorders, inherited metabolic disorders, HIV/AIDS research, vaccine development, and rare diseases.

Lentiviral vectors act as prominent tools to study gene function, expression, and regulation. The increased demand for such tools with increasing awareness about the potential of lentiviral vectors is directly contributing to the rising global lentiviral vectors market share.

Additionally, due to the strong ability of lentiviral vectors in used in developing personalized treatments for patients by targeting specific genetic mutations accounting for diseases is also driving the market growth. The continuous ongoing research and development activities on lentiviral vectors are being explored for innovative therapeutic approaches, including cancer immunotherapy, neurodegenerative disease treatment, and regenerative medicine which is further propelling the market growth.

Lentiviral Vectors Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Cobra Biologics Limited

• Sirion-Biotech GmbH

• Merck KGaA

• FinVector Oy

• Oxford Biomedica

• OriGene Technologies, Inc.

• Sino Biological Inc.

• Cell Biolabs, Inc.

• Batavia Biosciences B.V.

• Lonza

Key Highlights of the Report